Sol-Gel Technologies (NASDAQ:SLGL) has seen its target price dramatically increased from $6.00 to $50.00 by HC Wainwright in a research note released on Monday. This significant adjustment reflects a strong buy rating from the firm, suggesting a bullish outlook for the company’s stock.
In addition to the price target increase, HC Wainwright provided earnings estimates for Sol-Gel Technologies. They anticipate a loss of ($2.09) earnings per share (EPS) for Q3 2025, followed by a positive EPS of $0.40 in Q4 2025. For the full fiscal year 2025, the forecast stands at a loss of ($0.68) EPS. Projections continue into 2026, with expected losses of ($1.63) EPS in Q1, ($1.74) EPS in Q2, ($1.78) EPS in Q3, and ($1.47) EPS in Q4, culminating in an estimated ($6.60) EPS for the entire fiscal year.
Other brokerages have also offered their assessments of Sol-Gel Technologies. Weiss Ratings reaffirmed a “hold (c-)” rating on the stock in a note dated October 8, while Wall Street Zen upgraded the stock to a “buy” rating on September 13. Presently, one analyst has assigned a buy rating, and another has issued a hold rating. According to MarketBeat, the stock holds a consensus rating of “Moderate Buy” with an average target price of $50.00.
Recent Earnings Performance
On August 15, Sol-Gel Technologies reported its quarterly earnings, showcasing a remarkable performance. The company achieved an EPS of $4.17, significantly surpassing the consensus estimate of (0.67) by $4.84. This positive earnings report is notable for a company that has struggled with a negative return on equity of 11.80% and a net margin of 14.25%.
Revenue for the quarter reached $17.26 million, which is considerably higher than analyst expectations of $2.86 million. Looking ahead, sell-side analysts predict a modest EPS of (0.28) for the current fiscal year.
Overview of Sol-Gel Technologies
Sol-Gel Technologies Ltd., along with its subsidiary Sol-Gel Technologies Inc., is focused on the development of topical dermatological treatments for patients suffering from severe skin conditions, based in Israel. The company is best known for its products, including Twyneo, a once-daily, non-antibiotic topical cream for treating acne vulgaris, and Epsolay, a topical cream for managing papulopustular (subtype II) rosacea.
As the market watches Sol-Gel Technologies closely, the significant revision in its price target by HC Wainwright reflects growing confidence in the company’s potential for future growth. Investors and analysts alike will be keen to monitor the company’s performance in the coming quarters as it navigates the challenges and opportunities in the dermatological sector.
